30-year Gilead R&D vet Nor­bert Bischof­berg­er is start­ing over as staffer #5 at an up­start biotech — and he’s lov­ing it

Af­ter spend­ing the past 30 years be­fore the R&D mast at Gilead, ex-re­search chief Nor­bert Bischof­berg­er is start­ing over from scratch. 

This morn­ing, just a few weeks af­ter his for­mal de­par­ture from the head job at one of the world’s top 15 drug re­search or­ga­ni­za­tions, Bischof­berg­er is jump­ing on board at an up­start biotech with just 4 full time staffers. 

An­gela Koehler

He’s chipped in to an $18 mil­lion seed round — rough­ly 1/200th the size of this year’s R&D bud­get at Gilead — to launch Kro­nos Bio. The biotech in-li­censed a plat­form tech­nol­o­gy out of the lab of MIT pro­fes­sor An­gela Koehler fo­cused on mod­u­lat­ing tran­scrip­tion fac­tors in can­cer,  with two pre­clin­i­cal pro­grams fo­cused on MYC and the red hot an­dro­gen re­cep­tor tar­get. And they’re tak­ing a shot at break­ing new ground in can­cer R&D.

This isn’t a spur of the mo­ment de­ci­sion, Bischof­berg­er tells me. He start­ed ac­tive­ly hunt­ing around for a new biotech start­up idea in Jan­u­ary. And when Kite founder, biotech en­tre­pre­neur and ven­ture in­vestor Arie Bellde­grun was talk­ing over his plans for Kro­nos with Gilead chair­man John Mar­tin, Mar­tin point­ed him in Bischof­berg­er’s di­rec­tion, know­ing that he had be­gun to hunt for the right start­up.

“I want­ed to start my own com­pa­ny,” says Bischof­berg­er, “but it was a very vague idea, think­ing about AI and health­care.” In Jan­u­ary, he at­tend­ed a con­fer­ence on AI to ex­plore it more and came to the re­al­iza­tion that “every­body and their moth­er is do­ing AI. Then along came Arie.”

Arie Bellde­grun

With his back­ground and these kinds of con­nec­tions, Bischof­berg­er could just as eas­i­ly have raised $100 mil­lion-plus. But he’s in­tent on tak­ing a mea­sured ap­proach ear­ly on, hap­py to have in­vest­ed a chunk of his own mon­ey in the start­up to re­serve sub­stan­tial eq­ui­ty. And in ad­di­tion to the FTEs on board, em­ploy­ee #5 at Kro­nos al­so can tap 15 to 20 staffers un­der con­tract in In­dia.

Ex­cit­ed much?

 “I want to do it again,” says a cheer­ful Bischof­berg­er, “I’m 62, I feel like 42 and be­have like I’m 22… I’ve done it and seen it all, now I want to ap­ply it to my own ideas.”

John Mar­tin

Bischof­berg­er’s de­par­ture may have been a sur­prise to many, but these days ex­pe­ri­enced bio­phar­ma ex­ecs can prac­ti­cal­ly write their own tick­ets in biotech. George Scan­gos left Bio­gen to start Vir and David Meek­er left the helm at Gen­zyme to launch KSQ. Bellde­grun him­self went from the $12 bil­lion sale of Kite to Gilead straight in­to a start­up of his own, com­plete with an am­bi­tious li­cens­ing pact in place with Pfiz­er. An ex­o­dus of Big Phar­ma ex­ecs, mean­while, is pop­u­lat­ing the start­up world, in­ter­est­ed in grow­ing big new com­pa­nies on the back of promis­ing new tech­nolo­gies.

Why do it? In Bischof­berg­er’s view, it’s a chance to drop the myr­i­ad de­mands of a large or­ga­ni­za­tion, dom­i­nat­ed by HR is­sues and more, and get back in­to fo­cused drug de­vel­op­ment work.

Re­bec­ka Bellde­grun

Bischof­berg­er plans to stay on the West Coast, even though Kro­nos is in Cam­bridge, MA, and will be grow­ing the staff on the East Coast hub. But he counts his flight time as one of his most pro­duc­tive times, able to sep­a­rate from his sur­round­ings and con­cen­trate on the men­tal tasks at hand. So he doesn’t see com­mut­ing as a waste of time.

John Mar­tin likes it all. He vol­un­teered to jump in on the seed round for the Two Rivers port­fo­lio com­pa­ny. Oth­er in­vestors in­clude Omega Funds, Bell­Co Cap­i­tal and Vi­da Ven­tures, LLC. As part of the fi­nanc­ing Bischof­berg­er and Mar­tin, as well as Re­bec­ka Bellde­grun — physi­cian and wife of Kite founder Arie Belde­grun — and Otel­lo Stam­pac­chia joined the com­pa­ny’s board of di­rec­tors.


Im­age: Nor­bert Bischof­berg­er. KRO­NOS

Martin Shkreli [via Getty]

Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

Just days after Retrophin shed its last ties to founder Martin Shkreli, the biotech is reporting that the lead drug he co-invented flopped in a pivotal trial. Fosmetpantotenate flunked both the primary and key secondary endpoints in a placebo-controlled trial for a rare disease called pantothenate kinase-associated neurodegeneration, or PKAN.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Hal Barron. GSK

GSK's Hal Bar­ron her­alds their sec­ond pos­i­tive PhI­II for cru­cial an­ti-BC­MA ther­a­py, point­ing to a push for quick OKs in a crowd­ed field

Hal Barron has his second positive round of Phase III data in hand for his anti-BCMA antibody drug conjugate belantamab mafodotin (GSK2857916). And GSK’s research chief says the data paves the way for their drive in search of an FDA approval for treating multiple myeloma. 

It’s hard to overestimate the importance of this drug for GSK, a cornerstone of Barron’s campaign to make a dramatic impact on the oncology market and provide some long-lost excitement for the pharma giant’s pipeline. They’re putting this BCMA program at the front of that charge — looking to lead a host of rivals all aimed at the same target.

UP­DAT­ED: An em­bold­ened As­traZeneca splurges $95M on a pri­or­i­ty re­view vouch­er. Where do they need the FDA to hus­tle up?

AstraZeneca is in a hurry.

We learned this morning that the pharma giant — not known as a big spender, until recently — forked over $95 million to get its hands on a priority review voucher from Sobi, otherwise known as Swedish Orphan Biovitrum.

That marks another step down on price for a PRV, which allows the holder to slash 4 months off of any FDA review time.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Several biopharma companies have been working on expanding drug labels through the use of real world endpoints, combing through the data to find evidence of a drug’s efficacy for particular indications. But we’ve just begun. Real World Evidence is becoming an important part of every clinical development plan, in the soup-through-nuts approach used in building franchises.

I’ve recruited a panel of 3 top experts in the field — the first in a series of premium webinars — to look at the practical realities governing what can be done today, and where this is headed over the next few years, at the prodding of the FDA.

ZHEN SU — Merck Serono’s Senior Vice President and Global Head of Oncology
ELLIOTT LEVY — Amgen’s Senior Vice President of Global Development
CHRIS BOSHOFF — Pfizer Oncology’s Chief Development Officer

A premium subscription to Endpoints News is required to attend this webinar. Please upgrade to either an Insider or Enterprise plan for access. Already have Endpoints Premium? Please sign-in below. You can contact our Subscriptions team at help@endpointsnews.com with any issues.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Bob Smith, Pfizer

Pfiz­er is mak­ing a $500M state­ment to­day: Here’s how you be­come a lead play­er in the boom­ing gene ther­a­py sec­tor

Three years ago, Pfizer anted up $150 million in cash to buy Bamboo Therapeutics in Chapel Hill, NC as it cautiously stuck a toe in the small gene therapy pool of research and development.

Company execs followed up a year later with a $100 million expansion of the manufacturing operations they picked up in that deal for the UNC spinout, which came with $495 million in milestones.

And now they’re really going for it.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Video: Putting the AI in R&D — with Badhri Srini­vasan, Tony Wood, Rosana Kapeller, Hugo Ceule­mans, Saurabh Sa­ha and Shoibal Dat­ta

During BIO this year, I had a chance to moderate a panel among some of the top tech experts in biopharma on their real-world use of artificial intelligence in R&D. There’s been a lot said about the potential of AI, but I wanted to explore more about what some of the larger players are actually doing with this technology today, and how they see it advancing in the future. It was a fascinating exchange, which you can see here. The transcript has been edited for brevity and clarity. — John Carroll

Am­gen, Al­ler­gan biosim­i­lar of Roche's block­buster Rit­ux­an clears an­oth­er US piv­otal study 

Novartis $NVS may have given up, but Amgen $AMGN and Allergan $AGN are plowing ahead with their knockoff of Roche’s blockbuster biologic Rituxan in the United States.

Their copycat, ABP 798, was found to have a clinically equivalent impact as Rituxan — meeting the main goal of the study involving CD20-positive B-cell non-Hodgkin’s lymphoma patients. This is the second trial supporting the profile of the biosimilar. In January, it came through with positive PK results in patients with rheumatoid arthritis.

Trump ad­min­is­tra­tion re­vives bid to get drug list prices on TV ads

The Trump administration is not giving up just yet. On Wednesday, the HHS filed an appeal against a judge’s decision in July to overturn a ruling obligating drug manufacturers to disclose the list price of their therapies in television adverts — hours before it was stipulated to go into effect.

In May, the HHS published a final ruling requiring drugmakers to divulge the wholesale acquisition cost— of a 30-day supply of the drug — in tv ads in a bid to enhance price transparency in the United States. The pharmaceutical industry has vehemently opposed the rule, asserting that list prices are not what a typical patient in the United States pays for treatment — that number is typically determined by the type of (or lack thereof) insurance coverage, deductibles and out-of-pocket costs. Although there is truth to that claim, the move was considered symbolic in the Trump administration’s healthcare agenda to hold drugmakers accountable in a climate where skyrocketing drug prices have incensed Americans on both sides of the aisle.